Role of adrenoceptors in the regulation of dopamine/DARPP‐32...

来自 : 发布时间：2024-05-20

Free Access Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons Masato Hara, Department of Anesthesiology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorRyuichi Fukui, Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorEriko Hieda, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorMahomi Kuroiwa, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Japan Science of Technology Agency, CREST, Kurume, Fukuoka, JapanSearch for more papers by this authorHelen S. Bateup, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this authorTatsuhiko Kano, Department of Anesthesiology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorPaul Greengard, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this authorAkinori Nishi, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Japan Science of Technology Agency, CREST, Kurume, Fukuoka, Japan Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this author Masato Hara, Department of Anesthesiology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorRyuichi Fukui, Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorEriko Hieda, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorMahomi Kuroiwa, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Japan Science of Technology Agency, CREST, Kurume, Fukuoka, JapanSearch for more papers by this authorHelen S. Bateup, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this authorTatsuhiko Kano, Department of Anesthesiology, Kurume University School of Medicine, Kurume, Fukuoka, JapanSearch for more papers by this authorPaul Greengard, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this authorAkinori Nishi, Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Japan Science of Technology Agency, CREST, Kurume, Fukuoka, Japan Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USASearch for more papers by this author Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URLShare a linkShare onEmailFacebookTwitterLinked InRedditWechat AbstractJ. Neurochem. (2010) 113, 1046–1059.Abstract Studies in animal models of Parkinson’s disease have revealed that degeneration of noradrenaline neurons is involved in the motor deficits. Several types of adrenoceptors are highly expressed in neostriatal neurons. However, the selective actions of these receptors on striatal signaling pathways have not been characterized. In this study, we investigated the role of adrenoceptors in the regulation of dopamine/dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) signaling by analyzing DARPP-32 phosphorylation at Thr34 [protein kinase A (PKA)-site] in mouse neostriatal slices. Activation of β1-adrenoceptors induced a rapid and transient increase in DARPP-32 phosphorylation. Activation of α2-adrenoceptors also induced a rapid and transient increase in DARPP-32 phosphorylation, which subsequently decreased below basal levels. In addition, activation of α2-adrenoceptors attenuated, and blockade of α2-adrenoceptors enhanced dopamine D1 and adenosine A2A receptor/DARPP-32 signaling. Chemical lesioning of noradrenergic neurons mimicked the effects of α2-adrenoceptor blockade. Under conditions of α2-adrenoceptor blockade, the dopamine D2 receptor-induced decrease in DARPP-32 phosphorylation was attenuated. Our data demonstrate that β1- and α2-adrenoceptors regulate DARPP-32 phosphorylation in neostriatal neurons. Gi activation by α2-adrenoceptors antagonizes Gs/PKA signaling mediated by D1 and A2A receptors in striatonigral and striatopallidal neurons, respectively, and thereby enhances D2 receptor/Gi signaling in striatopallidal neurons. α2-Adrenoceptors may therefore be a therapeutic target for the treatment of Parkinson’s disease.Abbreviations used: AC adenylyl cyclase DARPP-32 dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa DSP-4 N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride IP immunoprecipitations LC locus coeruleus PKA protein kinase A SDS sodium dodecyl sulfate Noradrenaline has been shown to interact with the dopaminergic system and regulate psychomotor functions. In animal models of Parkinson’s disease, depletion of noradrenaline by degeneration of noradrenergic neurons or genetic deletion of dopamine β-hydroxylase potentiates the motor deficits of Parkinson’s disease (Srinivasan and Schmidt 2003; Rommelfanger etal. 2007). These deficits can be improved by noradrenaline replacement (Rommelfanger etal. 2007), indicating a critical role for noradrenaline in the motor dysfunction of Parkinson’s disease. Adrenoceptors are subdivided into three major classes by their differential coupling to G-proteins. α1-Adrenoceptors (α1A, α1B, α1D), coupled to Gq, activate phospholipase C; α2-adrenoceptors (α2A–2C), coupled to Gi, inhibit adenylyl cyclase (AC); and β-adrenoceptors (β1–3), coupled to Gs/olf, stimulate AC. It is known that pre-synaptic α2-adrenoceptors negatively regulate dopamine release from dopaminergic terminals (Trendelenburg etal. 1994; Yavich etal. 1997; Gobert etal. 2004). It is likely that noradrenaline also modulates dopamine receptor signaling post-synaptically in medium spiny neurons. However, information on the interaction between noradrenaline and dopamine receptor signaling in medium spiny neurons is limited. Despite the functional importance of noradrenaline in dopaminergic neurotransmission, the striatum receives only sparse noradrenergic innervation (Swanson and Hartman 1975; Aston-Jones 2004). However, certain types of adrenoceptors, such as β1-, α2A-, and α2C-adrenoceptors are expressed in the striatum (Nicholas etal. 1996; MacDonald etal. 1997). β1-Adrenoceptors were found to be expressed in medium spiny neurons by radioligand binding (Nahorski etal. 1979; Waeber etal. 1991) and immunohistochemistry (Pisani etal. 2003), and the loss of β1-adrenoceptors in the striatum was reported in the late stages of Huntington’s chorea (Waeber etal. 1991). α2A-Adrenoceptors are widely distributed in the brain including the striatum (MacDonald etal. 1997), and mediate the inhibition of monoamine release and metabolism (Trendelenburg etal. 1994; Bucheler etal. 2002; Ihalainen and Tanila 2004). Generally, they are associated with functions, such as sedation, analgesia, and hypotension (MacMillan etal. 1996; Lakhlani etal. 1997; Altman etal. 1999; Philipp etal. 2002). In contrast, α2C-adrenoceptors show a unique distribution pattern, and are most abundantly expressed in the striatum, olfactory tubercle, hippocampus, and cerebral cortex (Nicholas etal. 1996; MacDonald etal. 1997; Winzer-Serhan etal. 1997; Holmberg etal. 1999). α2C-Adrenoceptors are expressed in medium spiny neurons in the striatum (Holmberg etal. 1999), and are negatively coupled to AC via Gi (Lu and Ordway 1997; Zhang etal. 1999). α2C-Adrenoceptors are also expressed in dopaminergic neurons in the substantia nigra (Rosin etal. 1996; Lee etal. 1998) and possibly at dopaminergic terminals in the striatum. Together with α2A-adrenoceptors, they inhibit the release of dopamine (Bucheler etal. 2002). In mice lacking α2C-adrenoceptors, amphetamine-induced locomotor activity, startle reactivity, and aggressive behavior were enhanced, whereas pre-pulse inhibition was attenuated (Sallinen etal. 1998a,b). Opposite changes were reported in α2C-adrenoceptor over-expressing mice (Sallinen etal. 1998a,b). Thus, α2C-adrenoceptors likely play an inhibitory role in the regulation of motor and emotional functions and a modulatory role in the processing of sensory information (Scheinin etal. 2001). Dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) is selectively enriched in medium spiny neurons in the striatum, and plays an essential role in dopaminergic neurotransmission (Greengard etal. 1999; Svenningsson etal. 2004). Dopamine activates dopamine D1 receptors coupled to Gs/olf, leading to an activation of cAMP/ protein kinase A (PKA) signaling and the phosphorylation of DARPP-32 at Thr34 (the PKA-site). When DARPP-32 is phosphorylated on Thr34, it is converted into a potent inhibitor of protein phosphatase-1, and thereby controls the phosphorylation state and activity of many downstream physiological effectors, including various neurotransmitter receptors and voltage-gated ion channels (Svenningsson etal. 2004). The state of DARPP-32 phosphorylation at Thr34 is also regulated by various other signaling molecules, providing a mechanism for integrating dopamine and other neurotransmitter signals. Noradrenergic neurotransmission plays a critical role in the regulation of motor function by interacting with dopamine signaling, and noradrenaline replacement therapy has been proposed as a treatment for Parkinson’s disease (Grimbergen etal. 2009). However, the molecular mechanisms by which adrenoceptors regulate dopamine signaling in the striatum have not been investigated. In this study, we investigated the regulation of DARPP-32 phosphorylation by β and α-adrenoceptors. We find that activation of both types of receptors affects the phosphorylation of DARPP-32 at Thr34. Furthermore, activation of Gi by α2-adrenoceptors and subsequent inhibition of adenosine A2A receptor/Gs/PKA signaling are required for the actions of Gi-coupled D2 receptors in striatopallidal neurons. Male C57BL/6 mice at 6–8 weeks old were purchased from Japan SLC (Shizuoka, Japan). All mice used in this study were handled in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health. The Institutional Animal Care and Use Committee of Kurume University School of Medicine approved the specific protocols. Male C57BL/6 mice were killed by decapitation. The brains were rapidly removed and placed in ice-cold, oxygenated Krebs-HCO3− buffer (124 mM NaCl, 4 mM KCl, 26 mM NaHCO3, 1.5 mM CaCl2, 1.25 mM KH2PO4, 1.5 mM MgSO4, and 10 mM d-glucose, pH 7.4). Coronal slices (350 μm) were prepared using a vibrating blade microtome, VT1000S (Leica Microsystems, Nussloch, Germany). Striata were dissected from the slices in ice-cold Krebs-HCO3− buffer. Each slice was placed in a polypropylene incubation tube with 2 mL fresh Krebs-HCO3− buffer containing adenosine deaminase (10 μg/mL). The slices were pre-incubated at 30°C under constant oxygenation with 95% O2/5% CO2 for 60 min. The buffer was replaced with fresh Krebs-HCO3− buffer after 30 min of pre-incubation. Adenosine deaminase was included during the first 30 min of pre-incubation. Slices were treated with drugs as specified in each experiment. Drugs were obtained from the following sources: isoproterenol, propranolol, CGP20712A, ICI118551, cirazoline, UK14304, yohimbine, nortriptyline, GR113808, SB258585, SKF81297, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) from Sigma-Aldrich (St. Louis, MO, USA); CGS21680 from Tocris Cookson (Bristol, UK). After drug treatment, slices were transferred to Eppendorf tubes, frozen on dry ice, and stored at −80°C until assayed. Frozen tissue samples were sonicated in boiling 1% sodium dodecyl sulfate (SDS) containing 50 mM sodium fluoride and boiled for an additional 10 min. Small aliquots of the homogenate were retained for protein determination by the bicinchoninic acid protein assay method (Pierce, Rockford, IL, USA). Equal amounts of protein (100 μg) were separated by SDS/polyacrylamide gel electrophoresis (10% polyacrylamide gels), and transferred to nitrocellulose membranes (0.2 μm; Schleicher and Schuell, Keene, NH, USA). Immunoprecipitations of Flag- and Myc-tagged DARPP-32 in neostriatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc mice D1-DARPP-32-Flag/D2-DARPP-32-Myc transgenic mice express Flag- and Myc-tagged DARPP-32 under the control of dopamine D1 and D2 receptor promoters, respectively (Bateup etal. 2008). In the striatum, Flag-tagged DARPP-32 was shown to be expressed selectively in D1 receptor-enriched striatonigral neurons, and Myc-tagged DARPP-32 selectively in D2 receptor-enriched striatopallidal neurons. Using antibodies against Flag and Myc tags, we selectively immunoprecipitated DARPP-32 from D1 receptor- and D2 receptor-expressing neurons and analyzed the phosphorylation state of DARPP-32 in a neuronal subtype-specific manner. In each experiment, six striatal slices were prepared from one mouse, and were divided into three treatment conditions. In each treatment condition, six slices, collected from three mice (two slices from each mouse), were used for the analysis of DARPP-32 phosphorylation. Six striatal slices were sonicated in 720 μL of immunoprecipitation (IP) lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% SDS, 100 nM okadaic acid, phosphatase inhibitor cocktail (#P5726; Sigma-Aldrich), and protease inhibitor cocktail (#11873580001; Roche, Basel, Switzerland)]. After determination of protein concentration, 15 μg of protein was saved for the analysis of DARPP-32 phosphorylation in total striatal homogenate, and the residual homogenates were used for IP. In each IP from striatal homogenate, 50 μL of washed EZView Red anti-Flag M2 affinity gel (Sigma-Aldrich) and 45 μL of anti-Myc antibody (Novus Biologicals, Littleton, CO, USA) coupled to magnetic beads (3 μg of Myc antibody for every 5 μL of magnetic beads) (Dynabeads M-280 Tosylactivated; Invitrogen, Carlsbad, CA, USA) were added. The homogenate/antibody mixture was gently rotated overnight at 4°C. Following the overnight incubation, the Myc magnetic beads were separated from the homogenate/antibody mixture using a magnetic particle concentrator (Invitrogen), and then the Flag affinity gels were separated by centrifugation. The Myc magnetic beads and Flag affinity gels were washed with 1× phosphate-buffered saline three times. After the final wash, 30 μL of sample buffer was added and the samples were boiled for 2 min. Flag IP, Myc IP, and total striatal samples were loaded onto 4–12% polyacrylamide Bis-Tris gels (Bio-Rad, Hercules, CA, USA), separated by electrophoresis, and transferred to nitrocellulose membranes (0.2 μM; Schleicher and Schuell). In some experiments, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) was used to selectively lesion noradrenergic neurons in the locus coeruleus (LC) (Gesi etal. 2000; Rommelfanger etal. 2007). DSP-4 at a dose of 50 mg/kg or saline (0.1 mL/10 g body weight) was injected intraperitoneally (i.p.) to C57BL/6 mice. DSP-4 was dissolved in saline immediately before injection and used within 2 min to avoid degradation. After 7 days of DSP-4 or saline injection, neostriatal slices were prepared as described above and treated with SKF81297 or CGS21680. The membranes were immunoblotted using a phosphorylation state-specific antibody raised against DARPP-32 phospho-peptides: phospho-Thr34, the site phosphorylated by PKA (mAb-23, 1 : 750 dilution; CC500, 1 : 500–4000; Snyder etal. 1992). A monoclonal antibody (C24-5a, 1 : 7500 dilution) generated against DARPP-32 (Hemmings and Greengard 1986), which is not phosphorylation state-specific, was used to determine the total amount of DARPP-32. None of the experimental manipulations used in this study altered the total amount of DARPP-32. The membrane was incubated with a goat anti-mouse or rabbit Alexa 680-linked IgG (1 : 5000 dilution; Molecular Probes, Eugene, OR, USA) or a goat anti-mouse or rabbit IRDyeTM800-linked IgG (1 : 5000 dilution; ROCKLAND, Gilbertsville, PA, USA). Fluorescence at infrared wavelengths was detected by the Odyssey infrared imaging system (LI-COR, Lincoln, NE, USA), and quantified using Odyssey software. In an individual experiment, samples from control- and drug-treated slices were analyzed on the same immunoblot. For each experiment, values obtained for slices were calculated relative to values for the control or drug-treated slices, as described in figure legends. Normalized data from multiple experiments were averaged and statistical analysis was carried out as described in the figure legends. Under deep anesthesia induced with sodium pentobarbital, male C57BL/6 mice at 6–8 weeks old were perfused rapidly through the left ventricle with 50 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) at 23°C. Serial coronal sections 50 μm in thickness were cut with a vibrating microtome, VT1000S (Leica Microsystems). Sections were processed for immunohistochemistry with the use of the free-floating method as described (Nishi etal. 2008). Sections were incubated with a rabbit anti-β1-adrenoceptor antibody (A-272; 1 : 500; Sigma), a rabbit anti-α2C-adrenoceptor antibody (RA19064; 1 : 200 dilution; Neuromics, Edina, MN, USA), and a mouse anti-DARPP-32 antibody (C24-5a; 1 : 20 000 dilution) at 20°C for 7 days. Antibody binding was visualized with a fluorescein isothiocyanate-conjugated donkey anti-mouse IgG (1 : 100; Jackson ImmunoResearch, West Grove, PA) and a rhodamine red-conjugated donkey anti-rabbit IgG (1 : 100; Jackson ImmunoResearch). Sections were mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) and examined with a confocal laser-scanning microscope, LSM 5 PASCAL (Zeiss, Oberkochen, Germany). Effects of β-adrenergic agonists on DARPP-32 Thr34 phosphorylation in neostriatal slices Treatment of neostriatal slices with a non-selective β-adrenergic agonist, isoproterenol (10 μΜ), rapidly and transiently increased DARPP-32 Thr34 phosphorylation (Fig.1a). Isoproterenol increased the level of phospho-Thr34 DARPP-32 by fourfold within 1 min of incubation, and the increased level of phospho-Thr34 DARPP-32 subsequently returned to basal values at 10 min. The stimulatory effect of isoproterenol on DARPP-32 Thr34 phosphorylation was attenuated by a non-selective β-adrenergic antagonist, propranolol (10 μΜ) (Fig.1b), although propranolol itself did not affect the level of phospho-Thr34 DARPP-32. To rule out the possibility that isoproterenol increases DARPP-32 Thr34 phosphorylation by activating dopamine D1 receptors (Vanderheyden etal. 1986), the effect of isoproterenol was examined in the presence of a dopamine D1 receptor antagonist, SCH23390 (1 μM). Pre-treatment with SCH23390 did not affect the stimulatory effect of isoproterenol on DARPP-32 Thr34 phosphorylation. To determine the subtype of β-adrenoceptors involved in DARPP-32 Thr34 phosphorylation, neostriatal slices were pre-treated with a β1-adrenergic antagonist, CGP20712A (10 μΜ), or a β2-adrenergic antagonist, ICI118551 (10 μΜ). Pre-treatment with CGP20712A, but not ICI118551, attenuated the isoproterenol-induced increase in DARPP-32 Thr34 phosphorylation (Fig.1c), suggesting that activation of β1-adrenoceptors induces the phosphorylation of DARPP-32 at Thr34 in neostriatal neurons. Effect of a β-adrenergic agonist on dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) Thr34 phosphorylation in neostriatal slices. (a) Neostriatal slices were treated with a non-selective β-adrenergic agonist, isoproterenol (10 μM), for the indicated times. Typical immunoblots for detection of phospho-Thr34 DARPP-32 and total DARPP-32 in the same membrane are shown at the left of panel. (b and c) Neostriatal slices were pre-treated for 10 min with (b) a non-selective β-adrenergic antagonist, propranolol (10 μM), or a dopamine D1 receptor antagonist, SCH23390 (1 μM), or (c) a β1-adrenergic antagonist, CGP20712A (10 μM), or a β2-adrenergic antagonist, ICI118551 (10 μM), followed by the addition of isoproterenol (10 μM) for 1 min. (d) Neostriatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc mice were incubated with isoproterenol (Iso; 10 μM) for 1 min. Flag-tagged DARPP-32, expressed in D1 receptor-enriched striatonigral neurons, and Myc-tagged DARPP-32, expressed in D2 receptor-enriched striatopallidal neurons, were immunoprecipitated. The panel shows data from total striatal homogenate (Homog), Flag-tagged DARPP-32 in striatonigral neurons (D1-Flag) and Myc-tagged DARPP-32 in striatopallidal neurons (D2-Myc). Typical immunoblots for detection of phospho-Thr34 DARPP-32 and total DARPP-32 in the same membrane are shown at the left of panel. The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained with untreated slices. Data represent means ± SEM for 4–12 experiments. **p   0.01, ***p   0.001 compared with untreated slices; †p   0.05, †††p   0.001 compared with isoproterenol alone; §§§p   0.001 compared with SCH23390 alone; §p   0.05 compared with ICI118551 alone; one-way anova followed by Newman–Keuls test. We next examined whether activation of β1-adrenoceptors increases DARPP-32 phosphorylation in D1 receptor-enriched striatonigral and/or D2 receptor-enriched striatopallidal neurons, using neostriatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc transgenic mice (Bateup etal. 2008). Flag- and Myc-tagged DARPP-32 were immunoprecipitated from striatonigral and striatopallidal neurons, respectively, and the phosphorylation state of DARPP-32 at Thr34 in the two types of neurons was analyzed. Treatment of neostriatal slices with isoproterenol (10 μM) for 1 min increased the level of phospho-Thr34 DARPP-32 by approximately twofold in total striatal homogenates (Fig.1d). Isoproterenol increased the phosphorylation of both Flag- and Myc-tagged DARPP-32 at Thr34 by twofold, suggesting that isoproterenol activates the β1-adrenoceptor signaling cascades both in striatonigral and striatopallidal neurons. The results are consistent with immunohistochemical data, demonstrating that β1-adrenoceptors are expressed in all DARPP-32-positive striatal neurons (Fig.3a). Expression of β1- and α2C-adrenoceptors in the striatum. Double immunostaining of striatal tissues with (a) dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) and β1-adrenoceptor antibodies and (b) DARPP-32 and α2C-adrenoceptor antibodies. The expression of β1- and α2C-adrenoceptors was detected in many DARPP-32-positive neurons, suggesting their expression both in striatonigral and striatopallidal neurons. In agreement with Pisani etal. (2003), the expression of β1-adrenoceptors was also detected in DARPP-32-negative, large-sized neurons (a; arrows), presumably cholinergic interneurons. Scale bars, 10 μm. Effects of α1- and α2-adrenergic agonists on DARPP-32 Thr34 phosphorylation in neostriatal slices The role of α-adrenoceptors in the regulation of DARPP-32 Thr34 phosphorylation was examined in neostriatal slices. Treatment with a selective α1-adrenergic agonist, cirazoline (1 μΜ), did not affect the level of phospho-Thr34 DARPP-32 by 5 min of incubation (Fig.2a). However, treatment with a selective α2-adrenergic agonist, UK14304 (1 μΜ), increased DARPP-32 Thr34 phosphorylation by 2.5-fold within 1 min of incubation, and the increased level of phospho-Thr34 DARPP-32 returned to basal values at 5 min (Fig.2b). After 20 min of incubation with UK14304, the level of phospho-Thr34 DARPP-32 decreased slightly below basal values (81.0 ± 6.7% of control; p   0.05 with Student’s t-test, but not significant with one-way anova followed by Newman–Keuls test). The rapid and transient increase in DARPP-32 Thr34 phosphorylation induced by UK14304 was antagonized by an α2-adrenergic antagonist, yohimbine (1 μΜ) (Fig.2c). Immunohistochemical data showed that α2C-adrenoceptors, the predominant subtype of α2-adrenoceptors in the striatum, were expressed in all DARPP-32-positive neurons (Fig.3b). Effect of α1-adrenergic and α2-adrenergic agonists on dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) Thr34 phosphorylation in neostriatal slices. (a) Neostriatal slices were treated with a selective α1-adrenergic agonist, cirazoline (1 μM), for the indicated times. (b) Neostriatal slices were treated with a selective α2-adrenergic agonist, UK14304 (1 μM), for the indicated times. (c) Neostriatal slices were pre-treated with a selective α2-adrenergic antagonist, yohimbine (1 μM), for 15 min, followed by the addition of UK14304 (1 μM) for 1 min. (d) Neostriatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc mice were incubated with UK14304 (10 μM) for 30 s. Flag-tagged DARPP-32 and Myc-tagged DARPP-32 were immunoprecipitated. The panel shows data from total striatal homogenate (Homog), Flag-tagged DARPP-32 in striatonigral neurons (D1-Flag) and Myc-tagged DARPP-32 in striatopallidal neurons (D2-Myc). The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained with untreated slices. Data represent means ± SEM for four to nine experiments. *p   0.05, **p   0.01, ***p   0.001 compared with untreated slices; ††p   0.05 compared with UK14304 alone; one-way anova followed by Newman–Keuls test. We next examined whether UK14304 induces DARPP-32 Thr34 phosphorylation selectively in striatonigral or striatopallidal neurons or both types of neurons. In neostriatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc mice, treatment with UK14304 significantly increased the level of phopho-Thr34 DARPP-32 in total striatal homogenate, but the magnitude of the increase was less than that in C57BL/6 mice possibly because of strain differences. The rapid increase in DARPP-32 Thr34 phosphorylation induced by UK14304 was detected selectively in striatonigral but not striatopallidal neurons (Fig.2d). These results demonstrate a cell-type specific effect of α2-adrenoceptors in the striatum, although α2C-adrenoceptors are present in all medium spiny neurons. Interaction of α2-adrenoceptor signaling with dopamine D1 and adenosine A2A receptor signaling We next examined whether α2-adrenoceptors could modulate Golf/PKA/DARPP-32 signaling activated by dopamine D1 and adenosine A2A receptors. Pre-treatment with the α2-adrenergic antagonist, yohimbine (10 μM), did not affect the basal level of phospho-Thr34 DARPP-32. However, yohimbine enhanced the increase in DARPP-32 Thr34 phosphorylation induced by SKF81297 (1 μM) (Fig.4a) or CGS21680 (5 μM) (Fig.4b), suggesting that tonic activity of α2-adrenoceptors inhibits dopamine D1 and adenosine A2A receptor/PKA/DARPP-32 signaling in neostriatal neurons. To test this, we treated striatal slices with the α2-adrenergic agonist, UK14304 (1 μM for 20 min), which did not significantly affect the basal levels of phospho-Thr34 DARPP-32 in this series of experiments. As expected from antagonist experiments, UK14304 reduced the increase in DARPP-32 Thr34 phosphorylation induced by SKF81297 (1 μΜ) (Fig.4c) or CGS21680 (5 μM) (Fig.4d). These results suggest that α2-adrenoceptors negatively interact with dopamine D1 and adenosine A2A receptor/PKA/DARPP-32 signaling. Effect of α2-adrenoceptor blockade and activation on dopamine D1 and adenosine A2A receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) signaling in neostriatal slices. (a and b) Neostriatal slices were pre-treated with an α2-adrenergic antagonist, yohimbine (10 μM for 15 min), followed by the addition of (a) a dopamine D1 receptor agonist, SKF81297 (1 μM for 5 min), or (b) an adenosine A2A receptor agonist, CGS21680 (5 μM for 2 min). (c and d) Neostriatal slices were pre-treated with an α2-adrenergic agonist, UK14304 (1 μM for 20 min), followed by the addition of (c) a dopamine D1 receptor agonist, SKF81297 (1 μM for 5 min), or (d) an adenosine A2A receptor agonist, CGS21680 (5 μM for 2 min). The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained with untreated slices. Data represent means ± SEM for four experiments. *p   0.05, **p   0.01, ***p   0.001 compared with untreated slices; †p   0.05, ††p   0.01 compared with SKF81297 or CGS21680 alone; one-way anova followed by Newman–Keuls test. We also examined the role of β-adrenoceptors in dopamine D1 and adenosine A2A receptor signaling. Pre-treatment with the β-adrenergic antagonist, propranolol (10 μM), did not affect the SKF81297 (1 μM)-induced or CGS21680 (5 μM)-induced increase in DARPP-32 Thr34 phosphorylation (data not shown). We next examined whether α2-adrenoceptors also play a role in dopamine D2 receptor signaling. Treatment of slices with a dopamine D2 receptor agonist, quinpirole (1 μM), decreased the level of phospho-Thr34 DARPP-32, as previously reported (Nishi etal. 1997). Pre-treatment with yohimbine (10 μM) attenuated the decrease in DARPP-32 Thr34 phosphorylation induced by quinpirole (Fig.5), suggesting that activity of α2-adrenoceptors is required for the action of dopamine D2 receptor to down-regulate DARPP-32 phosphorylation in neostriatal neurons. Effect of α2-adrenoceptor blockade on dopamine D2 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) signaling in neostriatal slices. Neostriatal slices were pre-treated with an α2-adrenergic antagonist, yohimbine (10 μM for 10 min), followed by the addition of a dopamine D2 receptor agonist, quinpirole (1 μM for 10 min). The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained with untreated slices. Data represent means ± SEM for six to nine experiments. ***p   0.001 compared with untreated slices; †††p   0.001 compared with quinpirole alone; one-way anova followed by Newman–Keuls test. The expression of dopamine β-hydroxylase and noradrenaline transporters are reported to be low in the striatum (Swanson and Hartman 1975; Berridge etal. 1997; Moll etal. 2000; Moron etal. 2002; Arai etal. 2008), and therefore the striatum is thought to receive a sparse noradrenergic innervation. To determine whether the release and reuptake machinery of noradrenaline at noradrenergic terminals is functioning in the striatum, we examined the effect of nortriptyline on DARPP-32 phosphorylation. Nortriptyline inhibits the noradrenaline transporter with high potency (Ki 3.4 nM) and the serotonin transporter with low potency (Ki 161 nM), but does not affect the dopamine transporter (Ki 13 920 nM; Torres etal. 2003). Treatment of neostriatal slices with nortriptyline (100 nM) increased the level of phospho-Thr34 DARPP-32 by ∼fivefold within 30 s of incubation, and the increased level of phospho-Thr34 DARPP-32 returned to basal values at 2 min (Fig.6a). Effect of nortriptyline on dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) Thr34 phosphorylation in neostriatal slices. (a) Neostriatal slices were treated with nortriptyline (100 nM), an inhibitor of monoamine transporters relatively selective for noradrenaline transporters, for the indicated times. (b and c) Neostriatal slices were pre-incubated for 10 min with (b) CGP20712A (10 μM) plus yohimbine (1 μM) or (c) a 5-HT4 receptor antagonist, GR113808 (10 μM) plus a 5-HT6 receptor antagonist, SB258585 (10 μM), followed by the addition of nortriptyline (100 nM) for 30 s. The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained with untreated slices. Data represent means ± SEM for four to six experiments. **p   0.01, ***p   0.001 compared with untreated slices; †p   0.05 compared with nortriptyline alone; §p   0.05 compared with CGP20712A plus yohimbine; one-way anova followed by Newman–Keuls test. The nortriptyline-induced increase in DARPP-32 Thr34 phosphorylation was partially but significantly antagonized by CGP20712A (10 μΜ) plus yohimbine (1 μΜ) (Fig.6b); however, the antagonizing effect of either compound was not significant when slices were pre-incubated with CGP20712A or yohimbine alone (data not shown). We also examined the effect of serotonergic antagonists for 5-HT4 and 5-HT6 receptors, which were reported to be the serotonin receptor subtypes coupled to Gs/olf/cAMP/PKA signaling in the striatum (Svenningsson etal. 2002). Treatment with a 5-HT4 receptor antagonist, GR113808 (10 μM), plus a 5-HT6 receptor antagonist, SB258585 (10 μM), also partially attenuated the nortriptyline-induced increase in DARPP-32 Thr34 phosphorylation (Fig.6c). Pre-treatment with a dopamine D1 receptor antagonist, SCH23390 (1 μM), did not attenuate the effect of nortriptyline (data not shown). Taken together, these data reveal a significant contribution of striatal noradrenaline release to DARPP-32 T34 phosphorylation in medium spiny neurons. Since we also observed an attenuation of the nortriptyline effect by blocking serotonin receptors, it is likely that nortriptyline inhibited both noradrenaline and serotonin transporters in neostriatal slices, leading to increased extracellular noradrenaline and serotonin. Thus, nortriptyline increases phosphorylation of DARPP-32 via activation of β1- and α2-adrenoceptors and serotonin 5-HT4 and 5-HT6 receptors. Dopamine D1 and adenosine A2A receptor signaling in neostriatal slices from DSP-4-lesioned mice After determining that blockade of noradrenaline uptake in striatal slices affected DARPP-32 phosphorylation, we investigated whether depletion of noradrenaline in vivo had an effect on D1 or A2A receptor-mediated phosphorylation of DARPP-32. We injected mice with DSP-4 to selectively lesion noradrenergic neurons of the LC. The expression levels of tyrosine hydroxylase in the LC, determined by western blotting, decreased to 45.7 ± 2.9% of control (saline-treated mice; p   0.05; Student’s t-test) after 7 days of DSP-4 administration, but the levels of tyrosine hydroxylase in the striatum were not affected (103.5 ± 5.2% of control), indicating that DSP-4 selectively lesions noradrenergic neurons in the LC without lesioning dopaminergic neurons in the substantia nigra. We examined the effect of dopamine D1 and adenosine A2A receptor agonists on DARPP-32 Thr34 phosphorylation in neostriatal slices from saline- or DSP-4-treated mice. Treatment of slices with SKF81297 (1 μΜ) increased DARPP-32 Thr34 phosphorylation threefold from 5 to 15 min of incubation in saline-treated mice (p   0.001 compared with untreated slices; one-way anova followed by Newman–Keuls test; Fig.7a). In slices from DSP-4-treated mice, the SKF81297-induced increase in DARPP-32 Thr34 phosphorylation was significantly higher than that in slices from saline-treated mice at 10 and 15 min of incubation (p   0.05; two-way anova followed by Bonferroni test). Dopamine D1 and adenosine A2A receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) signaling in neostriatal slices from saline- and DSP-4-treated mice. Mice were intraperitoneally injected with saline or DSP-4, and neostriatal slices were prepared from the mice after 7 days of injection. Neostriatal slices from saline (closed circles)- or DSP-4 (open circles)-treated mice were treated with (a) a dopamine D1 receptor agonist, SKF81297 (1 μM), or (b) an adenosine A2A receptor agonist, CGS21680 (1 μM), for the indicated times. The levels of phospho-Thr34 DARPP-32 were quantified by the Odyssey infrared imaging system, and the data were normalized to values obtained from untreated slices in saline-treated mice. Data represent means ± SEM for six to eight experiments. *p   0.05, **p   0.01 compared with values in saline-treated mice; two-way anova followed by Bonferroni test. Treatment of slices with CGS21680 (1 μM) increased DARPP-32 Thr34 phosphorylation threefold from 30 s to 2 min of incubation in saline-treated mice (p   0.01 compared with untreated slices; one-way anova followed by Newman–Keuls test; Fig.7b). In slices from DSP-4-treated mice, the CGS21680-induced increase in DARPP-32 Thr34 phosphorylation was significantly greater than that in slices from saline-treated mice at 1 min of incubation (p   0.01; two-way anova followed by Bonferroni test). We also examined the effect of DSP-4-lesioning on dopamine D2 receptor signaling. Treatment with quinpirole (10 nM–1 μM for 10 min) decreased DARPP-32 Thr34 phosphorylation similarly in slices from saline- and DSP-4-treated mice. The findings demonstrate that the chemical lesioning of noradrenergic neurons by DSP-4 results in the enhancement of dopamine D1 and adenosine A2A receptor/PKA/DARPP-32 signaling in striatal neurons. We have demonstrated that β1- and α2-adrenoceptors regulate PKA/DARPP-32 signaling in the striatum (see Fig.8). Dopamine D1 and adenosine A2A receptor signaling was attenuated by prolonged activation of α2-adrenoceptors, whereas it was enhanced by pharmacological blockade of α2-adrenoceptors and chemical lesioning of noradrenergic neurons in the LC. This indicates that α2-adrenoceptors, coupled to Gi, are tonically active and counteract Gs/olf-coupled dopamine D1 and adenosine A2A receptor signaling in striatonigral and striatopallidal neurons, respectively. The tonic activity of Gi-coupled α2-adrenoceptors is also required for the action of dopamine D2 receptors, another Gi-coupled receptor expressed in striatopallidal neurons. Thus, α2-adrenoceptors induce two distinct effects on dopamine signaling: inhibition of dopamine D1 receptor signaling in striatonigral neurons and enhancement of dopamine D2 receptor signaling in striatopallidal neurons. Such functional features of α2-aderenoceptors suggest that α2-aderenoceptors could be a target of therapeutic drugs for Parkinson’s disease. Interaction of β1- and α2A/C-adrenoceptor signaling with dopamine D1 and D2 receptor signaling in the striatum. β1- and α2A/C-adrenoceptors regulate protein kinase A (PKA)/dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32) signaling both in striatopallidal and striatonigral neurons, in addition to the inhibitory regulation of dopamine (DA) release by α2A/C-adrenoceptors. In striatopallidal neurons, activation of α2A/C-adrenoceptors, coupled to Gi, inhibits adenosine A2A receptor/Gs/olf/adenylyl cyclase (AC)/PKA/DARPP-32 signaling, and therefore enhances dopamine D2 receptor/Gi signaling. In striatonigral neurons, activation of α2A/C-adrenoceptors inhibits dopamine D1 receptor/Gs/olf/AC/PKA/DARPP-32 signaling. Thus, α2A/C-adrenoceptors differentially regulate dopamine signaling in two pathways, and activation of α2A/C-adrenoceptors by noradrenaline (NA) is required for dopamine to elicit its regulatory role in motor function via D2 receptors. Despite the functional importance of noradrenaline in dopaminergic neurotransmission, striatum receives only sparse noradrenergic innervation (Swanson and Hartman 1975; Aston-Jones 2004). However, the presence of noradrenaline at the extracellular spaces in the striatum was demonstrated by microdialysis studies (Cenci etal. 1992; Li etal. 1998; Dawson etal. 2000; Gobert etal. 2004), and the synthesis of noradrenaline from dopamine in striatal tissues was detected in vitro (Udenfriend and Creveling 1959; Ross and Reis 1974) and in vivo (McGeer etal. 1963), suggesting the presence of dopamine β-hydroxylase activity in the striatum. Furthermore, the presence of noradrenaline transporter in the striatum was reported (Moll etal. 2000; Moron etal. 2002; Arai etal. 2008). Recently, Gobert etal. (2004) demonstrated that noradrenaline in the striatum was derived from noradrenergic terminals and its release was subject to inhibitory control by α2-adrenoceptors. It is also possible that noradrenaline may be synthesized by dopamine β-hydroxylase expressed in striatal cells other than noradrenergic terminals. We found that the relatively selective noradrenaline transporter inhibitor, nortriptyline, increased DARPP-32 Thr34 phosphorylation via activation of adrenergic as well as serotonergic receptors in neostriatal slices, indicating the presence of functional noradrenergic terminals in the striatum. This finding is supported by the fact that the lesioning of noradrenergic neurons by DSP-4 enhanced striatal dopamine D1 and adenosine A2A receptor/PKA/DARPP-32 signaling. Taken together, the presence of noradrenergic terminals in the striatum is supported by neuropharmacological and biochemical data, although contradictory data have also been reported (Versteeg etal. 1976; Oke etal. 1978). β1-Adrenoceptors are highly expressed in striatal neurons, including cholinergic interneurons (Nahorski etal. 1979; Pazos etal. 1985; Pisani etal. 2003). Immunohistochemical analysis revealed the expression of β1-adrenoceptors both in striatonigral and striatopallidal neurons. Activation of β1-adrenoceptors, but not of β2-adrenoceptors, by isoproterenol induced the up-regulation of cAMP/PKA signaling, leading to the phosphorylation of DARPP-32 at Thr34 in the two types of striatal medium spiny neurons. The isoproterenol-induced phosphorylation of DARPP-32 at Thr34 was not because of the release of dopamine and subsequent activation of D1 receptors (Reisine etal. 1982) or the cross activation of D1 receptors by isoproterenol (Vanderheyden etal. 1986), since the effect of isoproterenol was not antagonized by the dopamine D1 receptor antagonist. Under physiological conditions in vivo, β1-adrenoceptors might be activated by noradrenaline released from noradrenergic terminals and/or by physically released dopamine, resulting in increased excitability of both striatonigral and striatopallidal neurons because of activation of PKA/DARPP-32 signaling. Such changes in the activity of the basal ganglia circuit may play a role in psychomotor functions. The β-adrenergic antagonist, propranolol, has been used for the treatment of essential tremor and anxiety disorders (Emilien and Maloteaux 1998; Pahwa and Lyons 2003), although the mechanisms underlying its therapeutic effect are not understood. Whether the effects of β1-adrenoceptors on DARPP-32 phosphorylation in the two types of striatal neurons presented here relates to the pathophysiology of essential tremor or anxiety disorders remains to be determined. Activation of α2-adrenoceptors by UK14304 attenuated the dopamine D1 and adenosine A2A receptor-induced increase in DARPP-32 Thr34 phosphorylation in striatal neurons. Our previous studies using striatal slices from D1-DARPP-32-Flag/D2-DARPP-32-Myc mice (Bateup etal. 2008; Kuroiwa etal. 2008) demonstrated that activation of dopamine D1 and adenosine A2A receptors selectively stimulates DARPP-32 Thr34 phosphorylation in striatonigral and striatopallidal neurons, respectively. Taken together, these findings indicate that activation of α2-adrenoceptors inhibits PKA/DARPP-32 signaling in both types of striatal neurons. Pharmacological blockade of α2-adrenoceptors and chemical lesioning of noradrenergic neurons induced the enhancement of dopamine D1 and adenosine A2A receptor/PKA/DARPP-32 signaling, indicating that α2-adrenoceptors are activated under basal conditions and tonically inhibit PKA/DARPP-32 signaling in both striatopallidal and striatonigral neurons. It has been demonstrated that α2-adrenoceptors, specifically α2C-subtype adrenoceptors, are negatively coupled to AC in the striatum using mice with infusion of antisense oligonucleotides against α2C-adrenoceptor mRNA (Lu and Ordway 1997) and with targeted inactivation of the α2C-adrenoceptor gene (Zhang etal. 1999). The possibility that dopamine is the endogenous activator of α2-adrenoceptors in the striatum has been proposed (Zhang etal. 1999), because of the sparse noradrenergic innervation. However, the data presented here suggest that α2-adrenoceptors are tonically activated by noradrenaline, because lesioning of noradrenergic neurons with DSP-4 mimics the effect of α2-adrenoceptor antagonism. In behavioral studies, it has been shown that amphetamine-induced locomotor activity is enhanced in mice lacking α2C-adrenoceptors, whereas the opposite change is observed in mice over-expressing α2C-adrenoceptors (Sallinen etal. 1998b). Thus, α2C-adrenoceptors likely play an inhibitory role in the regulation of motor function under conditions of high dopamine tone (Scheinin etal. 2001). Our biochemical data demonstrate that activation of α2-adrenoceptors induces (i) down-regulation of dopamine D1 receptor/PKA signaling in striatonigral neurons, (ii) down-regulation of adenosine A2A receptor/PKA signaling in striatopallidal neurons, and (iii) up-regulation of dopamine D2 receptor signaling in striatopallidal neurons (Fig.8). The role of α2C-adrenoceptors in amphetamine-induced locomotor activity can be explained by the modulation of dopamine D1 receptor/PKA signaling in striatonigral neurons. Removal of the inhibitory effect of α2C-adrenoceptors on dopamine D1 receptor/PKA signaling and the subsequent activation of striatonigral neurons presumably results in the enhancement of amphetamine-induced locomotor activity. If α2C-adrenoceptors were predominantly to affect striatopallidal neurons, then removal of the modulatory effect of α2C-adrenoceptors on striatopallidal neurons would induce activation of adenosine A2A receptor/PKA signaling and inhibition of dopamine D2 receptor signaling, resulting in the activation of striatopallidal neurons and an attenuation of amphetamine-induced locomotor activity. Thus, when dopamine tone is high, the inhibitory role of α2C-adrenoceptors might be important to suppress the over-activation of dopamine D1 receptor/PKA signaling in striatonigral neurons. However, the role of α2C-adrenoceptors observed under conditions of amphetamine-induced high dopamine tone seems to be different from that under conditions of low dopamine tone in Parkinson’s disease, as described below. At early time points (30 s and 1 min), activation of α2-adrenoceptors induced a transient increase in DARPP-32 Thr34 phosphorylation selectively in striatonigral neurons. The effect was not mediated through activation of dopamine D1 receptors in striatonigral neurons by released dopamine, because a dopamine D1 receptor antagonist, SCH23390, failed to block the effect of α2-adrenoceptor activation (data not shown) and α2-adrenoceptors are known to pre-synaptically inhibit dopamine release in the striatum (Bucheler etal. 2002). Activation of α2-adrenoceptors has been reported to induce the release of GABA (Zhang and Ordway 2003) and phospholipase C-mediated activation of PKA (Karkoulias etal. 2007), both of which may result in the phosphorylation of DARPP-32 at Thr34 (Snyder etal. 1994). It is not clear why activation of α2-adrenoceptors induces DARPP-32 phosphorylation selectively in striatonigral neurons, since α2C-adrenoceptors are expressed in both striatonigral and striatopallidal neurons. It is possible that transient activation of dopamine D2 receptors counteracts the α2C-adrenoceptor-induced phosphorylation of DARPP-32 in striatopallidal neurons, although this is just speculation and requires further study. However, mechanisms for the activation of PKA/DARPP-32 signaling selectively in striatonigral neurons were not further investigated, because the α2-adrenoceptor-induced phosphorylation of DARPP-32 at early time points was relatively small and transient, and the physiological significance of this phenomenon is not clear. In animal models of Parkinson’s disease, the degeneration of noradrenaline neurons in addition to dopamine neurons is involved in motor deficits of Parkinson’s disease (Srinivasan and Schmidt 2003; Rommelfanger etal. 2007), and the symptoms of Parkinson’s disease are improved by restoration of noradrenaline (Rommelfanger etal. 2007). In addition, in reserpine-induced akinesia, administration of l-DOPA improves akinesia, and the effect of l-DOPA is reported to be mediated in part by the synthesis of noradrenaline and activation of α2-adrenoceptors (Dolphin etal. 1976a,b). These results indicate that noradrenaline plays a critical role in the regulation of motor functions by interacting with dopamine signaling pathways in the striatum. α2-Adrenoceptors expressed in striatopallidal neurons likely play a therapeutic role in Parkinson’s disease. Here, we find that activation of α2-adrenoceptors in striatopallidal neurons induces down-regulation of adenosine A2A receptor/PKA signaling and up-regulation of dopamine D2 receptor signaling (Fig.8). These modulatory effects of α2-adrenoceptors potentiate the action of dopamine through dopamine D2 receptors, which likely improves the symptoms of Parkinson’s disease. Indeed, it has been shown that clonidine, an α2-adrenoceptor agonist, itself increases locomotor activity (Hill and Brotchie 1999), and enhances locomotor activity induced by dopamine receptor agonists (Pycock etal. 1977), muscarinic receptor antagonists (Carlsson etal. 1991), and a κ-opioid receptor agonist (Hill and Brotchie 1999) in monoamine-depleted animals. Interestingly, α2-adrenoceptor antagonists, such as idazoxan are also reported to have antiparkinsonian effects and attenuate l-DOPA-induced dyskinesia (Grondin etal. 2000; Srinivasan and Schmidt 2004; Fornai etal. 2007). α2-Adrenoceptor antagonists have been demonstrated to enhance the release of noradrenaline by blocking pre-synaptic α2-adrenoceptors (Dennis etal. 1987). The increase in noradrenergic neurotransmission likely results in the potentiation of dopaminergic signaling (Dickinson etal. 1988; Mavridis etal. 1991), thereby inducing anti-parkinsonian effects. Both the inhibition of pre-synaptic α2-adrenoceptors, which activates noradrenergic neurotransmission, and the stimulation of post-synaptic α2-adrenoceptors could be a useful therapeutic approaches for the treatment of Parkinson’s disease. The therapeutic potential of either α2-adrenergic antagonists or agonists may be determined by the stage of Parkinson’s disease. When noradrenergic innervation is conserved in early stages, the α2-adrenoceptor antagonist is expected to improve the symptoms of Parkinson’s disease, whereas the α2-adrenoceptor agonist may be useful in late stages. Indirect and direct activation of α2-adrenoceptors by α2-adrenoceptor antagonists and agonists, respectively, likely potentiates dopamine D2 receptor signaling in striatopallidal neurons and inhibits dopamine D1 receptor signaling in striatonigral neurons. The modulation of dopaminergic signaling by α2-adrenoceptor activation may improve the symptoms of Parkinson’s disease and prevent the development of l-DOPA-induced dyskinesia (Santini etal. 2009). The long-term effects of α2-adrenoceptor antagonists and/or agonists in various stages of Parkinson’s disease need to be clarified. This research was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18300128 to A.N.) and grants from the U.S.P.H.S. (MH074866 and DA10044 to PG), the Michael Stern Parkinson’s Research Foundation (to PG) and the Department of Defense (DOD/USAMRAA W81XWH-09-1-402 to PG). The authors thank Yukako Terasaki, Keiko Fujisaki and Michiko Koga for excellent technical assistance.Kobilka B. K. and Hein L. (1999) Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56, 154– 161.Shen H. and Shoji M. (2008) Reuptake of l-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson’s disease via norepinephrine transporter. Synapse 62, 632– 635. Aston-Jones G. (2004) Locus coeruleus, A5 and A7 noradrenergic cell groups, in The Rat Nervous System ( G. Paxinos, ed.), pp. 259– 294. Asademic Press, San Diego.Heintz N. and Greengard P. (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11, 932– 939.Foote S. L. and Kelley A. E. (1997) Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27, 230– 241.Hadamek K. and Hein L. (2002) Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109, 819– 826.Svensson A. and Carlsson A. (1991) Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn Schmiedebergs Arch. Pharmacol. 343, 568– 573.Mandel R. J. and Bjorklund A. (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res. 581, 217– 228.Nguyen H. Q. and Li P. (2000) In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br. J. Pharmacol. 130, 23– 26.Carter C. and Scatton B. (1987) Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 241, 642– 649.Gadie B. and Tulloch I. F. (1988) Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology (Berl) 96, 521– 527.Jenner P. and Marsden C. D. (1976a) Modification of the l-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase. Eur. J. Pharmacol. 35, 135– 144.Jenner P. and Marsden C. D. (1976b) The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacol. Biochem. Behav. 4, 661– 670. Emilien G. and Maloteaux J. M. (1998) Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur. J. Clin. Pharmacol. 53, 389– 404.Ruggieri S. and Paparelli A. (2007) Noradrenaline in Parkinson’s disease: from disease progression to current therapeutics. Curr Med Chem 14, 2330– 2334.Bonaccorsi I. and Fornai F. (2000) The role of the locus coeruleus in the development of Parkinson’s disease. Neurosci. Biobehav. Rev. 24, 655– 668.Cistarelli L. and Millan M. J. (2004) Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J. Neurosci. Methods 140, 141– 152.Allen P. B. and Nairn A. C. (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435– 447.Roos R. A. and Bloem B. R. (2009) Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 9, 279– 290.Ladure P. and Bedard P. J. (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch. Pharmacol. 361, 181– 186. Hemmings Jr. H. C. and Greengard P. (1986) DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution. J. Neurosci. 6, 1469– 1481. Hill M. P. and Brotchie J. M. (1999) The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128, 1577– 1585.Kurose H. and Miettinen R. (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93, 1323– 1333. Ihalainen J. A. and Tanila H. (2004) In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse nucleus accumbens. J. Neurochem. 91, 49– 56.Paris H. and Flordellis C. (2007) Alpha2-adrenergic receptors activate cyclic AMP-response element-binding protein through arachidonic acid metabolism and protein kinase A in a subtype-specific manner. J. Neurochem. 103, 882– 895.Tanaka M. and Nishi A. (2008) Regulation of DARPP-32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J. Neurochem. 107, 1014– 1026.Maze M. and Limbird L. E. (1997) Substitution of a mutant alpha2a-adrenergic receptor via \"hit and run” gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Natl Acad. Sci. USA 94, 9950– 9955.Rosin D. L. and Lynch K. R. (1998) Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience 84, 1085– 1096.Wong D. T. and Bymaster F. P. (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136, 153– 161. Lu L. and Ordway G. A. (1997) Alpha2C-adrenoceptors mediate inhibition of forskolin-stimulated cAMP production in rat striatum. Brain Res. Mol. Brain Res. 52, 228– 234.Kobilka B. K. and Scheinin M. (1997) Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18, 211– 219.Piascik M. T. and Limbird L. E. (1996) Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273, 801– 803.Colpaert F. C. and Millan M. J. (1991) Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res. 562, 216– 224.Ling G. M. and McGeer P. L. (1963) Conversion of tyrosine to catecholamines by cat brain in vivo. Biochem. Biophys. Res. Commun. 13, 291– 296.Ruther E. and Huether G. (2000) Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res. Dev. Brain Res. 119, 251– 257.Rocha B. A. and Hope B. T. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22, 389– 395.Howlett D. R. and Redgrave P. (1979) Loss of beta-adrenoceptor binding sites in rat striatum following kainic acid lesions. Eur. J. Pharmacol. 60, 249– 252.Hokfelt T. and Pieribone V. A. (1996) The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol. Sci. 17, 245– 255.Snyder G. L. and Greengard P. (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147– 8155. etal. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 28, 10460– 10471.Keller R. and Adams R. N. (1978) Dopamine and norepinephrine enhancement in discrete rat brain regions following neonatal 6-hydroxydopamine treatment. Brain Res. 148, 245– 250. Pahwa R. and Lyons K. E. (2003) Essential tremor: differential diagnosis and current therapy. Am. J. Med. 115, 134– 142.Probst A. and Palacios J. M. (1985) Beta-adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res. 358, 324– 328.Brede M. and Hein L. (2002) Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R287– R295.Bernardi G. and Calabresi P. (2003) Activation of beta1-adrenoceptors excites striatal cholinergic interneurons through a cAMP-dependent, protein kinase-independent pathway. J. Neurosci. 23, 5272– 5282.Jenner P. G. and Marsden C. D. (1977) The interaction of clonidine with dopamine-dependent behaviour in rodents. Naunyn Schmiedebergs Arch. Pharmacol. 297, 133– 141.Cheramy A. and Glowinski J. (1982) A role for striatal beta-adrenergic receptors in the regulation of dopamine release. Brain Res. 241, 123– 130.Miller G. W. and Weinshenker D. (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl Acad. Sci. USA 104, 13804– 13809.Guyenet P. G. and Lynch K. R. (1996) Distribution of alpha 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J. Comp. Neurol. 372, 135– 165. Ross R. A. and Reis D. J. (1974) Effects of lesions of locus coeruleus on regional distribution of dopamine-beta-hydroxylase activity in rat brain. Brain Res. 73, 161– 166.Kobilka B. K. and Scheinin M. (1998a) Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J. Neurosci. 18, 3035– 3042.Kobilka B. K. and Scheinin M. (1998b) D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype. Neuroscience 86, 959– 965.Valjent E. and Fisone G. (2009) l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J. Neurochem. 108, 621– 633.Sallinen J. and Haapalinna A. (2001) Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 68, 2277– 2285.Nathanson J. A. and Greengard P. (1992) Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. J. Neurosci. 12, 3071– 3083.Fisone G. and Greengard P. (1994) Phosphorylation of DARPP-32 is regulated by GABA in rat striatum and substantia nigra. J. Neurochem. 63, 1766– 1771. Srinivasan J. and Schmidt W. J. (2003) Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17, 2586– 2592. Srinivasan J. and Schmidt W. J. (2004) The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? Naunyn Schmiedebergs Arch. Pharmacol. 369, 629– 638.Nomikos G. G. and Greengard P. (2002) DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl Acad. Sci. USA 99, 3188– 3193.Greengard P. (2004) DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269– 296. Swanson L. W. and Hartman B. K. (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J. Comp. Neurol. 163, 467– 505.Gainetdinov R. R. and Caron M. G. (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4, 13– 25.Starke K. and Limberger N. (1994) Presynaptic alpha 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn Schmiedebergs Arch. Pharmacol. 350, 473– 481. Udenfriend S. and Creveling C. R. (1959) Localization of dopamine-beta-oxidase in brain. J. Neurochem. 4, 350– 352.Kanarek L. and Vauquelin G. (1986) Epinephrine and norepinephrine stimulation of adenylate cyclase in bovine retina homogenate: evidence for interaction with the dopamine D1 receptor. Life Sci. 38, 1221– 1227.De Jong W. and Palkovits M. (1976) Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res. 113, 563– 574.Probst A. and Palacios J. M. (1991) Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington’s chorea and Parkinson’s disease. Synapse 8, 270– 280.Chen Y. and Leslie F. M. (1997) Expression of alpha 2 adrenoceptors during rat brain development—II. Alpha 2C messenger RNA expression and [3H]rauwolscine binding. Neuroscience 76, 261– 272.Haapalinna A. and MacDonald E. (1997) Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur. J. Pharmacol. 339, 113– 119. Zhang W. and Ordway G. A. (2003) The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res. Mol. Brain Res. 112, 24– 32.Zhu M. Y. and Ordway G. A. (1999) alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J. Pharmacol. Exp. Ther. 289, 1286– 1292. The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account. Can\'t sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username